Skip to main content

Vertex Pharmaceutic(VRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Latest News

3 No-Brainer Growth Stocks to Buy in 2023
Motley Fool - Fri Feb 3, 1:00PM CST
Motley Fool
Fri Feb 3, 1:00PM CST
These stocks all fell by double digits last year.
Why Editas Medicine's Shares Jumped This Week
Motley Fool - Fri Feb 3, 11:10AM CST
Motley Fool
Fri Feb 3, 11:10AM CST
The gene-editing biotech's shares have had a strong two-week run.
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Motley Fool - Fri Feb 3, 8:37AM CST
Motley Fool
Fri Feb 3, 8:37AM CST
These companies should be able to carry their momentum well beyond this year.
Is Editas Medicine Stock a Buy Now?
Motley Fool - Fri Feb 3, 5:15AM CST
Motley Fool
Fri Feb 3, 5:15AM CST
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
Motley Fool - Thu Feb 2, 8:53AM CST
Motley Fool
Thu Feb 2, 8:53AM CST
These stocks are growing steadily and have a solid history of enriching shareholders.
3 No-Brainer Stocks to Buy in February
Motley Fool - Thu Feb 2, 4:52AM CST
Motley Fool
Thu Feb 2, 4:52AM CST
Going with these stocks should be an easy decision.
The 10 Best Stocks to Buy in February 2023
Motley Fool - Wed Feb 1, 10:24AM CST
Motley Fool
Wed Feb 1, 10:24AM CST
These diversified growth stocks could add rocket fuel to your long-term investing portfolio.
A New Bull Market Could Arrive in February: 3 Stocks to Buy Now
Motley Fool - Wed Feb 1, 4:52AM CST
Motley Fool
Wed Feb 1, 4:52AM CST
The bulls could be about to take over again. And these stocks are poised to be big winners.
3 Things About CRISPR Therapeutics That Smart Investors Know
Motley Fool - Tue Jan 31, 9:00AM CST
Motley Fool
Tue Jan 31, 9:00AM CST
The gene-therapy specialist's near-term outlook is quite bullish.
The Best Stocks to Invest $20,000 in Right Now
Motley Fool - Fri Jan 27, 8:53AM CST
Motley Fool
Fri Jan 27, 8:53AM CST
These healthcare giants have plenty of room left to run.